UCB Grabs Candid’s BCMA T-Cell Engager – Here’s Why CGEM Investors Are Celebrating
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
/ 352 items
#XY Event-Driven Stocks↓
Mirum’s Volixibat Delivers Major Win in VISTAS Study – First Potential Treatment for Severe Itching in PSC
Mirum’s drug volixibat reduced severe itching in PSC patients in a Phase 2 trial; next step is FDA filing in 2026.
Assertio Shares Jump as Garda Raises All-Cash Buyout Offer to $21.80 Per Share ($153M Deal)
Garda raised bid to $21.80/share cash to buy Assertio, boosting stock ~17%. Deal gives shareholders higher, certain payout.
FDA Gives Green Light: Clene’s New ALS Drug Moves Closer to Faster Approval
FDA may fast-track Clene’s ALS drug CNM-Au8 after strong results, offering hope for longer life and slower disease progression.
“Game-Changer” Breast Cancer Drug News Triggers H.C. Wainwright Upgrade for Celcuity
Celcuity’s drug showed strong results in breast cancer, boosting survival and raising hopes it could become a new standard treatment.
FDA Approves First-Ever PROTAC Drug Veppanu for Advanced Breast Cancer with ESR1 Mutation
FDA approved Pfizer/Arvinas Veppanu pill for advanced breast cancer with ESR1 mutation, helping hormone-resistant cases.